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ABSTRACT
Aggregates of misfolded tau proteins (or just “tau” for brevity) play a crucial role in the progression of Alzheimer’s disease
(AD) as they correlate with cell death and accelerated tissue atrophy. Longitudinal positron emission tomography (PET) is
used to measure the extent of tau inclusions; and PET-based image biomarkers are a promising technology for AD diagnosis
and prognosis. Here, we propose to combine an organ-scale biophysical mathematical model and longitudinal PET to extract
characteristic growth patterns and spreading of tau. The biophysical model is a reaction-advection-diffusion partial differential
equation (PDE) with only two unknown parameters representing the spreading (the diffusion part of the PDE) and growth of tau
(the reaction part of the PDE). The advection term captures tissue atrophy and is obtained from diffeomorphic registration of
longitudinal magnetic resonance imaging (MRI) scans. We describe the method, present a numerical scheme for the calibration
of the growth and spreading parameters, perform a sensitivity study using synthetic data, and apply it to clinical scans from the
ADNI dataset. Despite having only two parameters, the model can reconstruct clinical scans quite accurately.
Introduction
Alzheimer’s disease is the sixth highest leading cause of death in the US (alz.org). Its complex evolution is
thought to be closely related to the formation and spreading of abnormal proteinaceous assemblies in the nervous
system. In particular, the misfolding of β-amyloid (Aβ) and tau proteins are believed to be key factors driving
the progression of Alzheimer’s1–3. These corruptive templates incite a chain reaction of protein misfolding,
by imposing their anomalous structure on benign molecules. Subsequent growth, fragmentation and further
spreading of such toxic proteins hampers proper function of the nervous system, leads to accelerated tissue
atrophy, necrosis, and ultimately causes death4–7.
Tau aggregates are primarily found in the axon bundle and rapidly spread along neuronal pathways to distant
locations, but also invade the extracellular space8. Understanding the distinct spatiotemporal growth patterns
and original seeding of corrupted protein templates is imperative in developing new treatment protocols and can
reveal important complimentary information to aid diagnosis and overall efficacy of therapy. Longitudinal PET
scans (using the F-AV-1451 tracer) can image tau spreading and lead to improved diagnosis and prognosis. Many
groups are designing image-analysis algorithms for this purpose9–12. Here we propose a complementary approach:
We employ a PDE model of tau propagation and calibrate its parameters using longitudinal PET scans. Our goal is
to estimate such rates of amplification of misfolded tau-protein aggregates and the rate of fragmentation and migration thereof
to distant parts of the brain. Our hypothesis is that an informative minimal model can produce biomarkers, which
can augment imaged-based approaches. Once calibrated, the current and future spatiotemporal spreading of tau
can be quantified using our model.
Contributions. The novelty of our work can be summarized as follows:
1) We solve an inverse problem to estimate patient specific, characteristic growth parameters describing the
spatiotemporal evolution of misfolded tau-protein throughout the brain based on longitudinal 3D tau-PET imaging
of AD subjects. We model tau progression as reaction-diffusion-advection PDE which accounts for both, atrophy
and tau propagation; atrophy is modeled using material transport with a velocity obtained from diffeomorphic
image registration, and is one-way coupled to tau progression.
2) We investigate and demonstrate invertibility and accuracy of estimation for such growth parameters. We
perform a sensitivity study with respect to the relative change in tau signal between scans, the effect of tissue
atrophy, and the effect of partial observations. Our results indicate good agreement for future prediction of tau
uptake compared to the true data.
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3) We test our method on clinical tau-PET scans, and study the sensitivity of our model to different subjects,
and algorithmic hyper-parameters. To our knowledge, this is the first study of its kind.
Related work. We believe organ-scale biophysical models hold an enormous promise in aiding clinical man-
agement of AD. Such models of protein misfolding gained momentum with the advent of the prion-paradigm
(misfolding chain-reaction) disease model. Models range from molecular level13, 14, to graph models15–18, and
kinetic equations19. Inspired by the successful application of such models in computational oncology20–23, we
use an organ level PDE-model which reflects the most dominant evolution patterns of tau propagation. For
AD, a similar model to the one we propose here has been recently proposed for prion-like diseases24, 25 but did
not consider the PET-based calibration problem. To the best of our knowledge, our method is the first one to
personalize a biophysical model of tau propagation.
Results
We examine the quality of biophysical model personalization, and the accuracy of subsequent prediction of
tau spreading. Specifically, we ask the following two questions: (i) How does the solution of (3) depend on
the time horizon T and the effects of tissue atrophy (modeled via material transport)? And (ii) how does our
method perform on clinical tau-PET scans? For the latter, we use clinical PET data from the Alzheimer’s Disease
Neuroimaging Initiative (ADNI)1 database.
Synthetic Data. We generate synthetic tau-PET data based on our physics-based model. Fig. 1 gives an illustration
of the data and test case setup. As underlying brain anatomy, we use (segmentations of) longitudinal T1 MRI
scans of an AD subject with significant tissue atrophy (cf. panel A in Fig. 1). The advection velocity v used to
couple the effect of tissue atrophy to tau spreading is obtained from diffeomorphic image registration between
segmentations of the T1 MRI. Synthetic tau data is generated using our reaction-diffusion-advection model for tau
evolution based on the tissue segmentation of the first time point, and ground truth parameters ρ? = 8, κ = 0.18,
and v? = v (see panel B in Fig. 1 for an illustration).
Performance Metrics. For our synthetic studies, we report relative errors eι = ιrec/ι?, ι ∈ {ρ,κ} in the reconstruction
of the characteristic growth parameters. We further report the relative data misfit µO = ‖OT(cT−dT)‖2/‖dT‖2 of the
calibrated model (at observation points defined by O), as well as the relative forecast errors µt = ‖c(t)−dt‖2/‖dt‖2 for
predicted tau concentration at future time points t ∈ {T′, T′′}.
Accuracy of Model Calibration and Tau Forecast
We study the sensitivity of model calibration and prediction to (i) varying time frames of image acquisition, and
(ii) the effect of tissue atrophy, one-way coupled via material transport in a synthetic setting, with known ground
truth values. For these synthetic tests, we set the observation threshold τobs to zero (i.e., observe all data). Results
are given in Tab. 1. We also study the sensitivity to a nonzero observation threshold in Tab. 2
Sensitivity to Small Relative Change in tau Signal. Tau misfolding, and, hence AD progression is an (initially)
slow process. In clinical practice, PET imaging is acquired in intervals of 8 to 15 months with varying, but typically
small relative change of measured tau SUV. Hence, we study the sensitivity of the model calibration to smaller
relative change in tau uptake. We consider different acquisition times T0 for the first tau snapshot d0, such that
the relative change in tau SUV between the two time points varies from 99% to 3%. Tab. 1 (runs #17–#24) shows
results for calibration (using the material transport model) and tau forecast. We observe a slight deterioration in
reconstruction accuracy of the true model parameters for smaller time horizons between consecutive scans. For
particularly small relative change in tau uptake values, we see larger errors and a trend of under-estimating the
growth parameters. Up to 10% relative change in tau SUV, relative errors, however, are still small with 5% and
below for ρ, and up to 20% for κ. Similarly the accuracy of tau forecast deteriorates marginally, but remains low
with errors of 3-13% for T′, and 5-26% for T′′ (see also panel C in Fig. 1).
1http://adni.loni.usc.edu/
2/11
Table 1. Model calibration and tau evolution forecasting for synthetic data. We study the sensitivity with respect to 1)
the time horizon T between consecutive scans, and 2) tissue atrophy (one-way coupled to tau spreading via material
transport). For 1), we consider varying image acquisition time points T0 for d0 with a relative change (∆ SUV) in tau signal
(between scans d0 and d1) ranging from 99% to 3%. For 2), we consider three different scenarios: I. Disregard tissue atrophy
and use structural MRI of T0 as material properties for tau-propagation; II. Like before but use MRI of T1; III. Account for
tissue atrophy via material transport, governed by a velocity field found from image registration of (segmented) T1 and T0
MRI. We report relative errors eρ and eκ for the inversion parameters (true values are ρ? = 8, κ? = 0.18). µT1 denotes the
relative data misfit in the inversion; µT′ and µT′′ denote forecast errors at future times T′ = 1.2, and T′′ = 1.5.
ID T0 T1 ∆ SUV ρ κ eρ eκ µT1 µT′ µT′′
#1
I.
T 0
M
R
I
0.00 1.00 99% 7.77 1.70E−1 2.91E−2 5.34E−2 3.37E−1 3.90E−1 4.42E−1
#2 0.56 1.00 80% 7.89 1.85E−1 1.37E−2 2.89E−2 3.03E−1 3.70E−1 4.29E−1
#3 0.72 1.00 60% 7.70 1.52E−1 3.70E−2 1.53E−1 2.56E−1 3.43E−1 4.18E−1
#4 0.83 1.00 40% 7.21 9.36E−2 9.93E−2 4.80E−1 1.91E−1 3.13E−1 4.17E−1
#5 0.92 1.00 20% 6.48 4.12E−2 1.90E−1 7.71E−1 1.12E−1 2.80E−1 4.27E−1
#6 0.96 1.00 10% 5.96 1.49E−2 2.55E−1 9.17E−1 6.03E−2 2.63E−1 4.39E−1
#7 0.98 1.00 5% 5.78 6.92E−3 2.77E−1 9.62E−1 3.09E−2 2.52E−1 4.43E−1
#8 0.99 1.00 3% 5.73 4.52E−3 2.84E−1 9.75E−1 1.56E−2 2.45E−1 4.43E−1
#9
II
.T
1
M
R
I
0.00 1.00 99% 7.53 1.59E−1 5.93E−2 1.18E−1 2.49E−1 2.66E−1 3.06E−1
#10 0.56 1.00 80% 7.71 1.65E−1 3.57E−2 8.40E−2 1.84E−1 2.22E−1 2.77E−1
#11 0.72 1.00 60% 7.70 1.56E−1 3.72E−2 1.36E−1 1.48E−1 2.01E−1 2.67E−1
#12 0.83 1.00 40% 7.58 1.37E−1 5.19E−2 2.41E−1 1.14E−1 1.83E−1 2.60E−1
#13 0.92 1.00 20% 7.28 1.07E−1 9.00E−2 4.06E−1 7.35E−2 1.66E−1 2.60E−1
#14 0.96 1.00 10% 6.83 7.46E−2 1.46E−1 5.86E−1 4.39E−2 1.61E−1 2.75E−1
#15 0.98 1.00 5% 6.31 4.14E−2 2.12E−1 7.70E−1 2.42E−2 1.69E−1 3.06E−1
#16 0.99 1.00 3% 6.02 2.36E−2 2.48E−1 8.69E−1 1.26E−2 1.77E−1 3.29E−1
#17
II
I.
A
dv
.,
T 0
M
R
I
0.00 1.00 99% 7.90 1.80E−1 1.31E−2 4.72E−4 2.38E−2 3.34E−2 5.23E−2
#18 0.56 1.00 80% 7.90 1.83E−1 1.20E−2 1.71E−2 9.74E−2 1.02E−1 1.11E−1
#19 0.72 1.00 60% 7.89 1.81E−1 1.37E−2 4.21E−3 9.21E−2 1.09E−1 1.27E−1
#20 0.83 1.00 40% 7.83 1.72E−1 2.16E−2 4.65E−2 7.30E−2 1.06E−1 1.33E−1
#21 0.92 1.00 20% 7.70 1.57E−1 3.71E−2 1.25E−1 4.61E−2 9.90E−2 1.38E−1
#22 0.96 1.00 10% 7.56 1.43E−1 5.45E−2 2.05E−1 2.66E−2 9.42E−2 1.43E−1
#23 0.98 1.00 5% 6.66 7.22E−2 1.68E−1 5.99E−1 1.76E−2 1.22E−1 2.19E−1
#24 0.99 1.00 3% 5.97 6.73E−2 2.54E−1 6.26E−1 9.89E−3 1.37E−1 2.64E−1
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Figure 1. Qualitative results for model calibration and tau evolution forecasting using synthetic data. Panel A illustrates structural differences induced by
tissue atrophy: a)–1 and a)–5 show original T1 MRI scans of an AD subject at time points T0 = 0 and T1 = 1; a)–2 through a)–4 show material advection of CSF to
account for tissue atrophy at intermediate time points; a)–5 and 6 show the magnitude and deformation gradient of the velocity, obtained from registration of T1 MRI (a
value of |∇v|< 1 ndicates contraction, a value above 1 expansion; the registration is performed from the second to the first snapshot). Panel B shows synthetic tau data
at different time points used for calibration and tau distribution at forecast time points T′ and T′′ (cf. Tab. 1). Panel C shows the forecast distribution c′ and c′′ of tau at
time points T′ and T′′ based on calibration for the three scenarios I-III from Tab. 1 and two different time horizons, along with the relative mismatch to the ground
truth (dark black indicates high error).4/11
Sensitivity to Effects from Tissue Atrophy (Material Transport). Next, we study the sensitivity of the model
personalization with respect to the material transport, coupling the effects of tissue atrophy to our tau evolution
model. For this first study, we consider three scenarios:
I. Disregard tissue atrophy and use structural MRI of time point T0 as material properties for tau-propagation;
II. Like above but use MRI of time point T1;
III. Account for tissue atrophy via material transport, governed by a velocity field found from image registration
of (segmented) MRI.
From Tab. 1 we observe that the effect of tissue atrophy is not negligible for the calibration of our model:
Disregarding the material transport which simulates effects of cortical thinning in our model, results in much
larger errors for both scenarios I. and II., compared to the full model in scenario III. Most prominently, smaller
relative change of tau SUV between scans results in a rapid and more drastic decline of accuracy for both
the calibrated growth parameters and the forecast of tau concentration, if the advection of material properties,
according to the cortical thinning, is disregarded. The differences in forecast of tau distribution at future time
points can be seen from!Fig. 1 (panel C) for the different scenarios. We conclude that the proposed model is
sensitive to the transport of material properties, and the coupling of tissue atrophy to tau spreading is not
negligible for model calibration.
Sensitivity to Partial Observations. We also study the sensitivity of the calibration step to partial observations,
meaning that the (synthetic) tau data d0 and dT is observed only up to 10%, 20%, 30% and 40% of its maximum
concentration. The calibration and forecast results are given in Tab. 2. We observe a strong sensitivity of our model
on the threshold of the observation operator, paired with large errors for the parameter reconstruction and tau
forecast for higher thresholds. Furthermore, the error is pronounced if the relative change of tau SUV between
scans becomes small.
From this first exploratory study using synthetic data, we find that small relative changes of tau SUV between
scans as well as partial observations severely complicate the calibration problem. The solution of the latter is
further hampered by the noise typically present in actual clinical tau-PET imaging. The presence of noise calls for
partial observations to focus attention to informative regions with change of tau SUV, and, consequently require
careful calibration of the observation threshold parameter.
Application to Clinical Data
We report reconstruction results in Tab. 3 and Figs. 2 and 2. PET scans are acquired 1-2 years apart; the number of
days between image acquisition is given by T. Not all cases have T1 MRI for the second time point; we do not
account for atrophy changes for these subjects.
Discussion
Perhaps the most interesting result in our study is that the estimated growth parameters show significant variability
across the different subjects. For example, we obtain values for ρ between 2 and 7, and κ ranges between 1.70E−1
and 1E−4. This demonstrates that our model is sensitive to patient-specific information and provides an indication
that the methodology could be clinically useful for differential diagnosis. Our model is minimal. Despite having
only two parameters, the model can reconstruct clinical scans quite accurately. The reconstructed parameters κ
and ρ could be used as biomarkers. Finally, the model can be run forward in time to predict tau propagation and
estimate AD progression, which can serve as an overall validation. Indeed, having more than two scans would
allow us to validate our model by using the first two scans to calibrate and the third scan to test the prediction.
This task is our first priority.
Second, the choice of the observation threshold τobs is critical, and strongly affects the calibration and prediction
result. We study the calibration result for three different choices of τobs. Figs. 2 and ?? show normalized PET scans
for two subjects with indicated observation contours in black for various values of τobs (panels a)–b)). For lower
values of τobs, larger regions of the tau scans are observed. This limits the flexibility of the model to account for
localized regional SUV variations (cf. localized intensity changes in tau-PET, panels a)–b) in Figs. 2 and ??). As
a result, the estimated proliferative parameter ρ decreases, and the diffusive parameter κ increases, for smaller
values of τobs. Finding an optimal choice for the hyper parameter τobs requires calibration to a large patient cohort.
For this first exploratory study, we opted for a simple model that captures the dynamics of tau propagation
and allows us to establish a calibration baseline upon which more complex models can be evaluated
5/11
Table 2. Sensitivity to Observation Threshold. We study the sensitivity with respect to the observation threshold τobs.
Synthetic data d0 and dT is observed only up to 10%, 20%, 30% and 40% of the maximum tau concentration, when
calibrating the model (compare rows 1–3 in figure; the red contour line indicates the observation threshold). We report relative
errors eρ and eκ for the inversion parameters (true values are ρ? = 8, κ? = 0.18), the calibration error µO at observation
points, and forecast errors µT′ and µT′′ . We consider two different time horizons with 80% and 20% relative change in tau
SUV, respectively. The last two rows of the figure show c′ tau concentrations at forecast time point T′, and corresponding
residual.
ID ∆ SUV τobs ρ κ eρ eκ µO µT′ µT′′
#25 80% 0.0 7.90 1.83E−1 1.20E−2 1.71E−2 9.74E−2 1.02E−1 1.11E−1
#26 80% 0.1 8.47 2.35E−1 5.87E−2 3.03E−1 9.42E−2 2.59E−1 5.06E−1
#27 80% 0.2 8.98 2.49E−1 1.22E−1 3.84E−1 8.38E−2 3.91E−1 6.33E−1
#28 80% 0.3 9.54 2.90E−1 1.92E−1 6.11E−1 7.53E−2 5.04E−1 7.19E−1
#29 80% 0.4 9.78 2.62E−1 2.23E−1 4.53E−1 6.65E−2 6.07E−1 7.87E−1
#30 80% 0.5 10.76 2.79E−1 3.45E−1 5.52E−1 6.70E−2 7.07E−1 8.47E−1
#31 20% 0.0 7.70 1.57E−1 3.71E−2 1.25E−1 4.61E−2 9.90E−2 1.38E−1
#32 20% 0.1 9.14 2.28E−1 1.43E−1 2.67E−1 6.97E−2 2.64E−1 5.09E−1
#33 20% 0.2 11.78 3.97E−1 4.73E−1 1.21E0 9.36E−2 4.00E−1 6.39E−1
#34 20% 0.3 12.52 1.93E−1 5.65E−1 7.41E−2 7.38E−2 5.28E−1 7.26E−1
#35 20% 0.4 13.09 3.74E−1 6.37E−1 1.08E0 1.28E−1 6.12E−1 7.89E−1
#36 20% 0.5 6.11 5.63E−2 2.36E−1 6.87E−1 1.60E−1 7.13E−1 8.49E−1
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Table 3. Model Personalization for Clinical Data. We report the calibrated growth parameters ρ and κ for seven AD
patients, taken from the ADNI database. We investigate sensitivity to the threshold τobs in the observation operator and
consider three different values τobs ∈ {0.6,0.4,0.2}. The time T between scans is given in days. If available, we register T1
MRIs of longitudinal snapshot, and account for atrophy (via material advection) in the personalization step (indicated by
“Adv”). For each applied threshold value, we report the relative mismatch µO at observation points, as well as the relative
error µ in the entire brain.
Observation Threshold τobs = 0.6 Observation Threshold τobs = 0.4 Observation Threshold τobs = 0.2
Subject ID T [d] Adv ρ κ µ µO ρ κ µ µO ρ κ µ µO
022_S_6013 401 yes 3.98 3.84E−2 8.30E−1 1.62E−1 1.01 2.35E−1 2.40E−1 1.36E−1 0.10 1.00E−4 1.36E−1 1.21E−1
023_S_1190 476 yes 4.16 4.47E−2 8.76E−1 3.75E−1 1.57 2.15E−1 3.44E−1 2.21E−1 0.57 2.50E−1 2.95E−1 2.33E−1
127_S_4301 477 no 4.00 1.88E−4 9.90E−1 3.53E−1 2.90 5.68E−3 9.66E−1 3.09E−1 1.34 1.89E−1 3.59E−1 2.26E−1
127_S_2234 660 no 2.94 1.74E−1 4.68E−1 2.40E−1 0.60 2.79E−1 2.87E−1 1.65E−1 0.23 2.97E−1 2.89E−1 2.06E−1
035_S_4114 426 yes 6.93 3.70E−2 9.08E−1 3.27E−1 2.96 1.46E−1 4.06E−1 2.63E−1 1.09 1.96E−1 2.96E−1 2.63E−1
033_S_4179 376 no 4.02 2.36E−2 9.26E−1 2.74E−1 2.46 1.86E−1 3.03E−1 1.83E−1 0.00 1.30E−3 1.96E−1 1.69E−1
941_S_4036 464 yes 3.54 1.27E−1 4.06E−1 2.07E−1 0.68 2.70E−1 2.34E−1 1.57E−1 0.00 9.04E−3 1.58E−1 1.41E−1
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Figure 2. Model Personalization for Clinical Data, ADNI subjects 035_S_4114 and 033_S_4179. The three rows
correspond to different observation thresholds τobs = 0.6 (first row), τobs = 0.4 (second row), and τobs = 0.2 (third row).
Shown are saggital and axial cuts of PET data and reconstruction. Panels a) and b) show the normalized PET for both
snapshots; the observation threshold is indicated by black contour lines. Panels c) and d) show the initial seeding and
predicted tau concentration, overlaid with the T1 MRI.
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Limitations and Future Directions. More complex models could be used for tau propagation. An important (and
relatively easy to implement) model improvement is to include anisotropic diffusion, especially for data with
longer time horizon T. Also in our model, the atrophy is computed from image registration and it is only one-way
coupled to tau. In our future work, we will evaluate such models6, 24. We remark that more complex models also
require more informative data; either more time snapshots of tau or larger time intervals between scans.
Another challenge is the normalization of longitudinal tau PET, especially for longitudinal studies where
relative change is small. The choice for a good reference region is not trivial, depends on the employed PET tracer,
and is sensitive to, e.g., registration errors26. PET normalization is ongoing research27, 28. Other challenges are
linked to lack of standardization in PET image acquisition protocols and subsequent normalization. Inconsistent
intensity changes, can be caused by several bio-physical factors such as age, weight change, and blood glucose level
of the patient; or by other imaging factors such as varying scanner models or image reconstruction algorithms29.
Dealing with such challenges would require cross-validation of our method with several subjects in order to select
the hyper-parameters in our scheme.
Methods
Models and Materials
Forward Model. To model the spatiotemporal evolution of misfolded tau-protein, we adopt the Fisher-Kolmogorov
equation30 coupled with an advection equation for material transport:
∂tc +∇ · (cv)− κDc− ρRc = 0, in ΩB × (0, T], (1a)
c(0) = c0 in ΩB , (1b)
∂tm+∇mv = 0, in Ω× (0, T], (1c)
m(0) =m0 in Ω. (1d)
This simple model captures the basic dynamics of the problem: (i) The growth and formation of tau aggregates,
and (ii) their subsequent fragmentation and spatial propagation. It further represents AD specific characteristics
such as slow early stage progression with a rapid acceleration after symptom onset, and the inevitable progression
of the disease: even a single corruptive protein will spread, and ultimately cause disease31.
Our model follows24, 25, but differs in a new image-driven transport term, that captures atrophy without a
mechanical model. In our case c = c(x, t) ∈ [0,1] is the tau concentration with initial seeding c0. Its evolution
over time t ∈ [0, T] in the three-dimensional brain domain ΩB ⊂Ω = [0,2pi]3 is governed by the coefficients of the
reaction and diffusion terms in (1a): The nonlinearity Rc = ρmc(1− c) with growth rate ρ provides a saturation
term expressing the maximal concentration of toxic proteins. ρm is a spatially variable coefficient, dependet on the
underlying material properties m = (mi(x, t))i=W, G, F, a vector of voxelwise probabilities for white matter (W), gray
matter (G), and cerebrospinal fluid with ventricles (F). Spatial spreading of tau is driven by extracellular diffusion and
axonal transport. This is modeled by the diffusion operator Dc =∇ · κm∇c, where κm = κ0I + (κi/κ− 1)T defines
the inhomogeneous (anisotropic) diffusion tensor. κ0 captures the inhomogeneous diffusion based on the material
properties m, while T expresses preferential direction of diffusion along the axon bundle weighted by κi, and
enables anisotropy. Tau does not invade the cerebrospinal fluid, and spreading occurs primarily in white matter32.
We approximate no-flux boundary conditions ∂ΩB via a penalty approach33, and use periodic boundary
conditions on ∂Ω.
Atrophy: Advection of Material Properties. Over time, tau aggregates disrupt cell function and ultimately cause
cell death and tissue atrophy (thinning of white and gray matter)6. We model tissue atrophy as image-driven
transport equation (1c)–(1d) of the spatiotemporal material properties m. As a result, tissue atrophy is one-way
coupled to tau spreading via the definition of the spatially variable diffusion and reaction coefficients.
The velocity field v is found via large-deformation diffeomorphic image registration of longitudinal MRI data,
and can be computed solving the inverse problem
min
~v
1
2
‖~m(1)− ~mT‖2L2(Ω) +
β
2
S(v) s.t. (1c)–(1d). (2)
Here, ~m0 and ~mT denote segmentations of T1 MRI, corresponding to the acquisition times t = 0 and t = T of
the tau-PET time-series. The regularization term S(v) is given as an H1-seminorm ∫Ω∑3i−1 |∇vi(x)|2 dx. For the
solution of (2) we use the registration software CLAIRE34. The proposed atrophy model is distinct from other
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approaches in the literature. In24, 25 the authors couple a reaction-diffusion equation to a mechanical deformation
model for atrophy, based on nonlinear elasticity.
Solving (1) defines the forward problem F (c0, cT ,~v,ρ,κ) = 0. Next, we discuss the image-driven calibration of
this model.
Model Calibration and Extraction of Tau-Spreading Characteristics
The model is personalized based on patient specific, tau-PET imaging data. That is, we estimate biophysical
growth parameters g = (ρ,κ) in (1) based on measurements of tau uptake value ratios (SUVR) from longitudinal
PET by solving a parameter estimation problem
min
g=(ρ,κ)
1
2
‖OT(cT − dT)‖2L2(Ω) s.t. F (c0, cT ,~v,ρ,κ) = 0, from (1), (3)
minimizing the discrepancy between predicted tau concentration cT = c(T) (based on the seeding c(0)) and the
target data dT . The observation operator Oi is defined as Oic := 1[di(x)> ε]c with threshold ε= τobs ·max(di) for
i = 0, T. In other words, points with uptake values below τobs percent of the maximum concentration of d0 and dT ,
respectively, are not observed. This is critical due to the low signal-to-noise ratio in PET imaging. Observation in
the entire brain would disregard localized relative changes of SUVR, and drive the growth parameters close to
zero. The seeding concentration c(0) is given by the observation points of the data d0 from the first time point
O0d0 =: c0. As a proof of concept, we only consider isotropic diffusion for the model calibration. The extension to
anisotropy is straightforward and will be realized in future work. Next, we discuss the numerical scheme for the
solution of (3).
Numerical Scheme
Numerical Solution of the Forward Problem. We employ a pseudo-spectral Fourier approach on a regular grid for
spatial discretization. That means all spatial differential operators are computed via a 3D fast Fourier Transform35.
For numerical solution of the forward problem, we employ a first-order operator-splitting method to split the tau
progression equation (1a) into a reaction, diffusion, and advection part. For the diffusion split, we use an implicit
Crank-Nicholson method, and solve the linear system with a preconditioned matrix-free CG method. The reaction
sub-steps are solved analytically. The hyperbolic transport equations are solved using an unconditionally stable
semi-Lagrangian time-stepping scheme to avoid stability issues and small, CFL restricted time-steps?, 36, 37. This
method requires evaluations of the space-time fields at off-grid locations, defined by the characteristic associated
with v. We compute off-grid evaluations using a cubic Lagrange polynomial interpolation model. We use nt = 100
time steps of size ∆t = 0.01 for the time integration.
Numerical Optimization. The optimization problem (3) is solved using a bound constrained, limited memory
BFGS quasi-Newton solver globalized with Armijo line-search. The gradient is computed using a first-order
accurate finite difference scheme with~h =
√
emach~g, for ~g = (ρ,κ)T . We terminate the optimization after a gradient
reduction of 4 orders of magnitude (relative to the initial guess). To keep the optimizer within feasible bounds,
and prevent bad local minima, we define bound constraints κmin = 1E−4, and κmax = 1, ρmin = 0.1, and ρmax = 15.2
Workflow Summary
For the evaluation on clinical data, we use seven AD subjects from the ADNI database as outlined in Tab. 3.
Imaging data is processed using FSL38 by applying the following steps: (i) longitudinal T1 MRI are rigidly
registered to the first time point using FLIRT39; (ii) longitudinal tau-PET images are rigidly registered to the
first time point T1 MRI; (iii) aligned T1 images are skull-stripped using BET40; (iv) registered T1 brain masks are
applied in PET space to obtain the skull-stripped PET image; (v) skull-stripped T1 images are segmented using
FAST41; (vi) PET images are individually normalized with average tau uptake value in the cerebellum. For the last
step, the cerebellum is extracted from a registered labeled standard template.
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